120 related articles for article (PubMed ID: 27941763)
1. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.
van Gelder M; de Wreede LC; Bornhäuser M; Niederwieser D; Karas M; Anderson NS; Gramatzki M; Dreger P; Michallet M; Petersen E; Bunjes D; Potter M; Beelen D; Cornelissen JJ; Yakoub-Agha I; Russell NH; Finke J; Schoemans H; Vitek A; Urbano-Ispízua Á; Blaise D; Volin L; Chevallier P; Caballero D; Putter H; van Biezen A; Henseler A; Schönland S; Kröger N; Schetelig J
Bone Marrow Transplant; 2017 Mar; 52(3):372-380. PubMed ID: 27941763
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.
Hill BT; Ahn KW; Hu ZH; Aljurf M; Beitinjaneh A; Cahn JY; Cerny J; Kharfan-Dabaja MA; Ganguly S; Ghosh N; Grunwald MR; Inamoto Y; Kindwall-Keller T; Nishihori T; Olsson RF; Saad A; Seftel M; Seo S; Szer J; Tallman M; Ustun C; Wiernik PH; Maziarz RT; Kalaycio M; Alyea E; Popat U; Sobecks R; Saber W
Biol Blood Marrow Transplant; 2018 Mar; 24(3):581-586. PubMed ID: 29032274
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation.
Schetelig J; de Wreede LC; van Gelder M; Andersen NS; Moreno C; Vitek A; Karas M; Michallet M; Machaczka M; Gramatzki M; Beelen D; Finke J; Delgado J; Volin L; Passweg J; Dreger P; Henseler A; van Biezen A; Bornhäuser M; Schönland SO; Kröger N
Bone Marrow Transplant; 2017 Apr; 52(4):552-560. PubMed ID: 28112746
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
[TBL] [Abstract][Full Text] [Related]
5. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
[TBL] [Abstract][Full Text] [Related]
6. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.
Goldman JM; Majhail NS; Klein JP; Wang Z; Sobocinski KA; Arora M; Horowitz MM; Rizzo JD
J Clin Oncol; 2010 Apr; 28(11):1888-95. PubMed ID: 20212247
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation.
Shimoni A; Labopin M; Savani B; Volin L; Ehninger G; Kuball J; Bunjes D; Schaap N; Vigouroux S; Bacigalupo A; Veelken H; Sierra J; Eder M; Niederwieser D; Mohty M; Nagler A
J Hematol Oncol; 2016 Nov; 9(1):118. PubMed ID: 27821187
[TBL] [Abstract][Full Text] [Related]
9. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
10. Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates.
Nivison-Smith I; Simpson JM; Dodds AJ; Ma DD; Szer J; Bradstock KF
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1323-30. PubMed ID: 19747641
[TBL] [Abstract][Full Text] [Related]
11. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.
Kharfan-Dabaja MA; Kumar A; Hamadani M; Stilgenbauer S; Ghia P; Anasetti C; Dreger P; Montserrat E; Perales MA; Alyea EP; Awan FT; Ayala E; Barrientos JC; Brown JR; Castro JE; Furman RR; Gribben J; Hill BT; Mohty M; Moreno C; O'Brien S; Pavletic SZ; Pinilla-Ibarz J; Reddy NM; Sorror M; Bredeson C; Carpenter P; Savani BN
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2117-2125. PubMed ID: 27660167
[TBL] [Abstract][Full Text] [Related]
12. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma.
Klyuchnikov E; Bacher U; Woo Ahn K; Carreras J; Kröger NM; Hari PN; Ku GH; Ayala E; Chen AI; Chen YB; Cohen JB; Freytes CO; Gale RP; Kamble RT; Kharfan-Dabaja MA; Lazarus HM; Martino R; Mussetti A; Savani BN; Schouten HC; Usmani SZ; Wiernik PH; Wirk B; Smith SM; Sureda A; Hamadani M
Bone Marrow Transplant; 2016 Jan; 51(1):58-66. PubMed ID: 26437062
[TBL] [Abstract][Full Text] [Related]
14. Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).
Schetelig J; de Wreede LC; Andersen NS; Moreno C; van Gelder M; Vitek A; Karas M; Michallet M; Machaczka M; Gramatzki M; Beelen D; Finke J; Delgado J; Volin L; Passweg J; Dreger P; Schaap N; Wagner E; Henseler A; van Biezen A; Bornhäuser M; Iacobelli S; Putter H; Schönland SO; Kröger N;
Br J Haematol; 2017 Aug; 178(4):521-533. PubMed ID: 28589551
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
[TBL] [Abstract][Full Text] [Related]
16. Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality--a single institution experience.
Chakupurakal G; Leitzke S; Langerbeins P; Schiller J; Schneider PM; Holtick U; Shimabukuro-Vornhagen A; Theurich S; Chemnitz J; Hallek M; von Bergwelt-Baildon M; Scheid C
Ann Hematol; 2015 Oct; 94(10):1717-25. PubMed ID: 26259502
[TBL] [Abstract][Full Text] [Related]
17. A retrospective analysis of treatment outcomes in adult T cell leukemia/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: A single-center experience.
Kawada H; Yoshimitsu M; Nakamura D; Arai A; Hayashida M; Kamada Y; Maekawa K; Fujino S; Arima M; Arima N; Tabuchi T; Inoue H; Hamda H; Suzuki S; Matsushita K; Arima N
Biol Blood Marrow Transplant; 2015 Apr; 21(4):696-700. PubMed ID: 25542158
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia.
Moreno C; Villamor N; Colomer D; Esteve J; Martino R; Nomdedéu J; Bosch F; López-Guillermo A; Campo E; Sierra J; Montserrat E
J Clin Oncol; 2005 May; 23(15):3433-8. PubMed ID: 15809449
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis.
Aulakh S; Reljic T; Yassine F; Ayala E; Chavez JC; Chanan-Khan A; Pinilla-Ibarz J; Kumar A; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2021 Mar; 14(1):33-40. PubMed ID: 32473105
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.
Sorror ML; Maris MB; Sandmaier BM; Storer BE; Stuart MJ; Hegenbart U; Agura E; Chauncey TR; Leis J; Pulsipher M; McSweeney P; Radich JP; Bredeson C; Bruno B; Langston A; Loken MR; Al-Ali H; Blume KG; Storb R; Maloney DG
J Clin Oncol; 2005 Jun; 23(16):3819-29. PubMed ID: 15809448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
